Possibilities of using Fosinopril, an angiotensinconverting enzyme inhibitor, combined with Diltiazem, a non-dihydropyridine calcium antagonist, as first-line therapy in the treatment of arterial hypertension (clinical case)

Author:

Ostroumova O. D.1,Goloborodova I. V.2

Affiliation:

1. Federal State Budgetary Educational Institution of Higher Education «Yevdokimov Moscow State University of Medicine and Dentistry» of the Ministry of Health of the Russian Federation; Federal State Budgetary Educational Institution of Higher Education «Pirogov Russian National Research Medical University» of the Ministry of Health of Russia.

2. Federal State Budgetary Educational Institution of Higher Education «Yevdokimov Moscow State University of Medicine and Dentistry» of the Ministry of Health of the Russian Federation.

Abstract

The article exemplified the successful experience of using combination therapy consisting of fosinopril, an angiotensin-converting enzyme inhibitor, and diltiazem, a non-dihydropyridine calcium antagonist, in a patient with a history of arterial hypertension, sinus tachycardia and bronchial asthma. The authors proved the high antihypertensive efficacy and safety of the therapy, its favourable effect on the daily profile of blood pressure and heart rate, and strong organ-protective properties, the ability to reduce the degree of left ventricular hypertrophy and microalbuminuria level.

Publisher

Remedium, Ltd.

Subject

General Medicine

Reference39 articles.

1. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;(00):1–98. doi:10.1093/eurheartj/ehy339.

2. Forouzanfar M.H., Liu P., Roth G.A., Ng M., Biryukov S., Marczak L. et al. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA. 2017;317(2):165-182. doi:10.1001/ jama.2016.19043.

3. Danilorskaya Yu.A., Zheleznykh E.A., Privalova E.V., Belenkov Yu.N., Schendrygina A.A., Pavlov N.A. Target organ damage in patients with hypertensive disease: possibility of management. Problemy Zhenskogo Zdorovya. 2016;11(2):5-12 (In Russ).

4. Launer L.J., Masaki K., Petrovitch H., Foley D., Havlik R.J. The assotiation between midlife blood pressure levels and late–life cognitive function. The Honolulu – Asia Aging Study. JAMA. 1995;274:1846–1851.

5. Yaffe K., Vittinghoff E., Pletcher M.J., Hoang T.D., Launer L.J., Whitmer R.A. et al. Early Adult to Midlife Cardiovascular Risk Factors and Cognitive Function. Circulation. 2014;129(15):1560–1567. doi:10.1161/circulationaha.113.004798.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3